Ken Griffin Arcturus Therapeutics Holdings Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$24.35 - $44.39 $63,310 - $115,414	2,600 Added 24.3%	13,300 $323,000
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $384,129 - $528,777	-12,300 Reduced 53.48%	10,700 $361,000
Q4 2023 Feb 14, 2024	BUY	$17.71 - $32.97 $159,390 - $296,730	9,000 Added 64.29%	23,000 $725,000
Q3 2023 Nov 14, 2023	SELL	$25.44 - $37.35 $318,000 - $466,875	-12,500 Reduced 47.17%	14,000 $357,000
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $172,368 - $232,992	7,200 Added 37.31%	26,500 $760,000
Q1 2023 May 15, 2023	BUY	$14.72 - $23.97 $54,464 - $88,689	3,700 Added 23.72%	19,300 $462,000
Q4 2022 Feb 14, 2023	BUY	$14.14 - $23.06 $220,584 - $359,736	15,600 New	15,600 $264,000

186

25.9M

320K

153K

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $551M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.